---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-072706"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:18:53.951749+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Madrigal raises ~$574M in public offering for Rezdiffra launch

## Summary
- Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.
- Net proceeds estimated at ~$574M; underwriters have 30-day option for up to 346,153 additional shares.
- Proceeds to fund commercial launch of Rezdiffra (resmetirom) in the U.S. and for general corporate purposes.
- Closing expected March 21, 2024; lock-up agreements for directors and officers for 60 days.
- Underwriters include Goldman Sachs, Jefferies, Cowen, Evercore, Piper Sandler.

## SEC filing metadata
- accession: 0001193125-24-072706
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/0001193125-24-072706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/d774533d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-072706
- JSON: https://secwatch.observer/filing/0001193125-24-072706.json
- Plain text: https://secwatch.observer/filing/0001193125-24-072706.txt

## Key facts
- Material Agreements
  MADRIGAL PHARMACEUTICALS, INC. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co valued at approximately $574.0 million (effective 2024-03-18).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co
  - Value: approximately $574.0 million
  - Effective: 2024-03-18
  source text: On March 18, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Goldman Sachs & Co. LLC, Jefferies LLC, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler & Co, as representatives of the several underwriters named therein (the “Underwriters”), for the sale of (i) 750,000 shares of common stock (the “Shares”) of the Company, $0.0001 par value per share (the “Common Stock”), and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase 1,557,692 shares of Common Stock in an underwritten public offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157601/000119312524072706/0001193125-24-072706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.